论文部分内容阅读
目的探讨人自体肿瘤细胞凋亡抗原负载的树突状细胞(DC)疫苗的实验室制备、临床应用安全性及初步疗效。方法 1例卵巢腺瘤Ⅱ～Ⅲ级,(种植灶)低分化腺癌患者,右卵巢癌术后22个月,发现腹腔转移半个月。患者签署知情同意书后,造血动员,无菌100ml抗凝全血,制备DC疫苗。收获DC疫苗前对培养上清进行细菌内毒素、细菌、真菌及支原体检测。检查合格后分4次腹股沟淋巴结富集区皮内注射。在回输前1天及每次回输后第3天抽血,进行血常规、肝功能、白介素(IL)系列及自然杀伤(NK)细胞项目检查。结果制备的DC疫苗质量检查合格,回输后患者无任何不适反应。血常规及肝功能值均在正常范围内,无明显变化,IL-2、IL-4和IL-12有明显提高,NK细胞回输后也提高至约2.45～3.40倍。结论自体肿瘤细胞凋亡抗原负载的DC疫苗回输是安全的,且显示出一定的疗效。
OBJECTIVE: To study the laboratory preparation, clinical safety and preliminary efficacy of human DCs vaccinated with tumor antigen. Methods One case of ovarian adenoma grade Ⅱ ~ Ⅲ, poorly differentiated adenocarcinoma of (foci), right ovarian cancer 22 months after operation, abdominal metastasis was found for half a month. Patients signed informed consent, hematopoietic mobilization, sterile 100ml anticoagulant whole blood, preparation of DC vaccine. Bacterial endotoxins, bacteria, fungi and mycoplasma were tested on the culture supernatant prior to harvest of the DC vaccine. After passing the examination 4 points inguinal lymph node enrichment zone intradermal injection. Blood samples were collected on day 1 before reinfusion and on day 3 after each reinfusion for routine blood tests, liver function, interleukin (IL) and natural killer (NK) cell counts. Results The quality of the prepared DC vaccine was qualified, and the patients did not have any discomfort reaction after transfusion. Blood and liver function values were within the normal range, no significant change, IL-2, IL-4 and IL-12 were significantly improved, NK cells also increased after reinfusion to 2.45 ~ 3.40 times. CONCLUSION: The reintroduction of autologous tumor cell apoptosis-antigen-loaded DC vaccine is safe and shows some curative effect.